bullish
Remegen Co Ltd (9995.HK) - Commercialized RC18 + IPO On SSE STAR Market = New Chapter & Challenges
239 Views15 Mar 2021 09:12
The article analyzed RemeGen's first commericalized product RC18, the challenges in R&D failure, fierce competition, commercialization and production capacity, the future outlook of RC48 and IPO plan.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Industry Report - Insights on China Biological Drug Market18 Mar 2021
- Pre-IPO Acotec Scientific Holdings - First-Mover Advantage Together with Challenges17 Mar 2021
- Bio-Thera Solutions (688177.CH) - What's Next for Bio-Thera After R&D Setbacks and Years of Losses?16 Mar 2021
- Remegen Co Ltd (9995.HK) - Commercialized RC18 + IPO On SSE STAR Market = New Chapter & Challenges15 Mar 2021
- Genor Biopharma (6998.HK) - Here Is Why the Stock Price Decreased by About 50%11 Mar 2021
- A Different Angle - RemeGen Vs Akeso (Insights on Valuation)08 Nov 2020
- Pre-IPO RemeGen - Insights on Two Core Products RC18 & RC4823 Oct 2020
x